Skip to main content
OpenTrials
Completed

NCT Number: NCT04454099

A Comparison of Different Fecal Occult Blood Test for Colorectal Cancer Screening

Colorectal cancer is a leading cause of cancer-related morbidity and mortality. CRC-related death can be prevented through fecal occult blood test screening. Because of economic and high sensitivity, fecal immunochemical test is recommended for screening population of CRC. The purpose of this study is to compare the accuracy of 4 different fecal occult blood testing in medium and high risk screening population in Chinese.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Qilu Hospital

Jinan, Shandong, 250001, China

About this study

Colorectal cancer (CRC) is one of the most common cancer worldwide, and cause a huge number of cancer-associated mortality. CRC screening has been shown to be effective in reducing the incidence of, and mortality from, CRC. There are several recommended screening options for screening population of CRC, including colonoscopy and fecal occult blood testing (FOBT) .Colonoscopy has higher sensitivity and specificity than FOBT for detecting advanced colorectal neoplasia but also has several disadvantages, including higher cost and poorer compliance. Therefore, many patients prefer FOBT to colonoscopy. FOBT includes guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT). FIT includes quantitative FIT (qFIT) and qualitative FIT. qFIT can provide a value of concentration of hemoglobin in stool and are increasingly recommended for CRC. In China, the most common use FOBT is qualitative FIT and the comparison of quantitative and qualitative FIT is lack in screening population of CRC in Chinese. To add to the evidence on FIT performance characteristics for detection of CRC, the investigators design this research to compare qFIT with other 3 qualitative FOBT(two of them are colloidal gold qualitative FITs and one of them is chemical and immunologic combined detection)in medium and high risk screening population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults 50-75 years old;
  • Asia-Pacific Colorectal Screening score(APCS): medium or high risk.

Exclusion criteria

  • APCS score: low risk;
  • People with history of intestinal surgery;
  • People with history of CRC;
  • People with history of inflammatory bowel disease, ischemic enteritis, vascular malformation of intestine or other disease resulting in intestinal tract bleeding;
  • People with symptoms including visible rectal bleeding, hematuria, severe and acute diarrhea and Bristol feces score 7th type;
  • Pregnancy, lactation or menstrual phase;
  • Severe congestive heart failure or other sever disease cause cannot tolerate colonoscopy.

Treatment and study plan

4 kind of FOBT and colonoscopy with pathological examination

Diagnostic Test

Detect Hb in stool by 4 kind of FOBT and detect colon lesion using colonoscopy and pathological examination.

Primary outcomes

  1. The accuracy of 4 kind of FOBTs to diagnose CRC.

    Time frame: 6 months

    The sensitivity, specificity, positive predictive value and negative predictive value of these 4 FOBTs to detect CRC.

  2. The accuracy of 4 kind of FOBTs to diagnose advanced colorectal neoplasm.

    Time frame: 6 months

    The sensitivity, specificity, positive predictive value and negative predictive value of these 4 FOBTs to detect advanced colorectal neoplasm.

  3. The accuracy of 4 kind of FOBTs to diagnose advanced adenoma.

    Time frame: 6 months

    The sensitivity, specificity, positive predictive value and negative predictive value of these 4 FOBTs to detect advanced adenoma.

  4. Develop a predictive model of CRC or advanced colorectal neoplasm which includes qFIT.

    Time frame: 6 months

    Develop a predictive model of CRC or advanced colorectal neoplasm which includes qFIT, age ,sex, CRC family history and so on.

Secondary outcomes

  1. Explore the cost-benefit ratio of one or two-sample of qFIT.

    Time frame: 6 month

    Explore the cost-benefit ratio of one or two-sample of qFIT.

  2. Explore the reason of false positive of qFIT

    Time frame: 6 month

    Calculate false positive rate of the 4 kind of FOBTs. and count the case number of inflammatory bowel disease, colonic diverticulitis, hemorrhoids, upper gastrointestinal disease or medical factors that cause false positive of qFIT.

  3. Explore the effect of aspirin or other anticoagulants to the diagnose accuracy of qFIT

    Time frame: 6 month

    Count sensitivity and specificity with or without patients who take aspirin or other anticoagulants.

Sponsors and collaborators

Lead sponsor

Shandong University

Other

Registry information

Official study title

A Comparison of Quantitative Fecal Immunochemical Test and Qualitative Fecal Occult Blood Test for Colorectal Cancer Screening in Medium and High Risk Screening Population

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jul 1, 2020
Registry last updated
May 4, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.